These results establish that bone marrow CCR2+/CX3CR1+ cells, when incubated in glioma-derived factors, acquire a phenotype capable of disrupting the proliferation and function of both CD4- and CD8-expressing T cells. This evidence concerns the gene CX3CR1 and glioma.